BiotechTube

Durvalumab / Tremelimumab Combination Therapy

Phase 1/2Active
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pediatric Cancer

Conditions

Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies

Trial Timeline

Mar 7, 2019 → Dec 30, 2024

NCT ID
NCT03837899

About Durvalumab / Tremelimumab Combination Therapy

Durvalumab / Tremelimumab Combination Therapy is a phase 1/2 stage product being developed by AstraZeneca for Pediatric Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03837899. Target conditions include Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies.

What happened to similar drugs?

3 of 19 similar drugs in Pediatric Cancer were approved

Approved (3) Terminated (0) Active (16)
✅Boosted AtazanavirBristol Myers SquibbApproved
✅Atazanavir + RitonavirBristol Myers SquibbApproved
✅IgPro10CSLApproved
🔄candsartan cilexetilAstraZenecaPhase 3
🔄basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroidsNovartisPhase 3
🔄VAL489 + VAL489 matching placeboNovartisPhase 3
🔄Entecavir + Lamivudine + Pegylated Interferon Alfa-2ARochePhase 3

Hype Score Breakdown

Clinical
9
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03837899Phase 1/2Active

Competing Products

20 competing products in Pediatric Cancer

See all competitors
ProductCompanyStageHype Score
RamucirumabEli LillyPhase 1
29
erlotinib + etoposideAstellas PharmaPhase 2
27
Mitoxantrone Hydrochloride Liposome + Irinotecan + VincristineSun PharmaceuticalPhase 1
33
Perampanel Oral Suspension + Perampanel TabletEisaiPhase 2
42
Eribulin MesylateEisaiPhase 1
29
Decitabine + DecitabineEisaiPhase 2
27
Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once dailySumitomo PharmaPhase 1
29
Remimazolam Tosilate for injection + Propofol InjectionJiangsu Hengrui MedicinePhase 2/3
45
Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or LinezolidAstraZenecaPhase 2/3
38
candsartan cilexetilAstraZenecaPhase 3
40
Rotavirus VaccineMerckPre-clinical
18
basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroidsNovartisPhase 3
40
VAL489 + VAL489 matching placeboNovartisPhase 3
40
LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696NovartisPhase 2/3
38
EverolimusNovartisPhase 2
35
Corticosteroids + Cyclosporine + mycophenolate mofetilRochePhase 2
27
Entecavir + Lamivudine + Pegylated Interferon Alfa-2ARochePhase 3
40
Blinatumomab for InjectionAmgenPhase 1
25
EtanerceptAmgenPhase 3
40
DenosumabAmgenPhase 3
40